{"title":"方案：COVID-19感染后新发糖尿病：系统评价和荟萃分析方案：系统评价。","authors":"Emma Cocking, Joseph Daher, Majid Alabbood","doi":"10.1002/cl2.70069","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Emerging evidence suggests that coronavirus disease 2019 (COVID-19) infection may cause diabetes mellitus in patients without a prior history of the condition.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>This review aims to determine the incidence of new-onset diabetes mellitus in COVID-19 patients compared to individuals without COVID-19, including rates of diabetic ketoacidosis, hyperglycaemia, mortality, and intensive care unit admission. Subgroup analyses will investigate patients receiving corticosteroid therapy for COVID-19, patients admitted to hospital due to COVID-19, and the incidence of new-onset diabetes mellitus in relation to diabetes mellitus worldwide. The incidence of new-onset diabetes mellitus post-infection after a 6–12-month follow-up will also be reported.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines and is registered in PROSPERO (CRD42023457569). Eligible studies will include published and peer-reviewed cohort studies in English, after 1 December 2019. PubMed, Medline, Embase, and Scopus will be systematically searched. Included studies should compare new-onset diabetes mellitus incidence in COVID-19 patients against a control group without COVID-19. Two independent reviewers will extract data from included studies and assess risk of bias using the Newcastle-Ottawa quality assessment scale. A random-effects meta-analysis will compare the relative risk of new-onset diabetes mellitus post COVID-19 infection compared to non-infected individuals.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The findings of this review will contribute to understanding the bidirectional relationship between COVID-19 and diabetes mellitus and inform clinical management strategies for patients at risk.</p>\n </section>\n \n <section>\n \n <h3> Systematic Review Registration</h3>\n \n <p>PROSPERO CRD42023457569.</p>\n </section>\n </div>","PeriodicalId":36698,"journal":{"name":"Campbell Systematic Reviews","volume":"21 4","pages":""},"PeriodicalIF":7.1000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481428/pdf/","citationCount":"0","resultStr":"{\"title\":\"PROTOCOL: New-Onset Diabetes Mellitus Post COVID-19 Infection: A Protocol for Systematic Review and Meta-Analysis: A Systematic Review\",\"authors\":\"Emma Cocking, Joseph Daher, Majid Alabbood\",\"doi\":\"10.1002/cl2.70069\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Emerging evidence suggests that coronavirus disease 2019 (COVID-19) infection may cause diabetes mellitus in patients without a prior history of the condition.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>This review aims to determine the incidence of new-onset diabetes mellitus in COVID-19 patients compared to individuals without COVID-19, including rates of diabetic ketoacidosis, hyperglycaemia, mortality, and intensive care unit admission. Subgroup analyses will investigate patients receiving corticosteroid therapy for COVID-19, patients admitted to hospital due to COVID-19, and the incidence of new-onset diabetes mellitus in relation to diabetes mellitus worldwide. The incidence of new-onset diabetes mellitus post-infection after a 6–12-month follow-up will also be reported.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines and is registered in PROSPERO (CRD42023457569). Eligible studies will include published and peer-reviewed cohort studies in English, after 1 December 2019. PubMed, Medline, Embase, and Scopus will be systematically searched. Included studies should compare new-onset diabetes mellitus incidence in COVID-19 patients against a control group without COVID-19. Two independent reviewers will extract data from included studies and assess risk of bias using the Newcastle-Ottawa quality assessment scale. A random-effects meta-analysis will compare the relative risk of new-onset diabetes mellitus post COVID-19 infection compared to non-infected individuals.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The findings of this review will contribute to understanding the bidirectional relationship between COVID-19 and diabetes mellitus and inform clinical management strategies for patients at risk.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Systematic Review Registration</h3>\\n \\n <p>PROSPERO CRD42023457569.</p>\\n </section>\\n </div>\",\"PeriodicalId\":36698,\"journal\":{\"name\":\"Campbell Systematic Reviews\",\"volume\":\"21 4\",\"pages\":\"\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481428/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Campbell Systematic Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cl2.70069\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SOCIAL SCIENCES, INTERDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Campbell Systematic Reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cl2.70069","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SOCIAL SCIENCES, INTERDISCIPLINARY","Score":null,"Total":0}
PROTOCOL: New-Onset Diabetes Mellitus Post COVID-19 Infection: A Protocol for Systematic Review and Meta-Analysis: A Systematic Review
Background
Emerging evidence suggests that coronavirus disease 2019 (COVID-19) infection may cause diabetes mellitus in patients without a prior history of the condition.
Objective
This review aims to determine the incidence of new-onset diabetes mellitus in COVID-19 patients compared to individuals without COVID-19, including rates of diabetic ketoacidosis, hyperglycaemia, mortality, and intensive care unit admission. Subgroup analyses will investigate patients receiving corticosteroid therapy for COVID-19, patients admitted to hospital due to COVID-19, and the incidence of new-onset diabetes mellitus in relation to diabetes mellitus worldwide. The incidence of new-onset diabetes mellitus post-infection after a 6–12-month follow-up will also be reported.
Methods
This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines and is registered in PROSPERO (CRD42023457569). Eligible studies will include published and peer-reviewed cohort studies in English, after 1 December 2019. PubMed, Medline, Embase, and Scopus will be systematically searched. Included studies should compare new-onset diabetes mellitus incidence in COVID-19 patients against a control group without COVID-19. Two independent reviewers will extract data from included studies and assess risk of bias using the Newcastle-Ottawa quality assessment scale. A random-effects meta-analysis will compare the relative risk of new-onset diabetes mellitus post COVID-19 infection compared to non-infected individuals.
Conclusion
The findings of this review will contribute to understanding the bidirectional relationship between COVID-19 and diabetes mellitus and inform clinical management strategies for patients at risk.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
